Clinical Trial Update: A Pilot Trial With Subcutaneous Alemtuzumab and Oral Fludarabinephosphate for the Determination of Safety, Efficacy and Molecular Profiling for the Prediction of Response [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating subcutaneous alemtuzumab with oral fludarabine phosphate for safety, efficacy, and molecular profiling to predict response in chronic l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Alemtuzumab (Alemtuzumab)
• Fludarabine phosphate (Fludarabine phosphate)

Snippet

Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie | Conditions: B-cell Chronic Lymphocytic Leukemia | Phase 2 | Status: COMPLETED